Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2022 / Cilt: 56 - Sayı: 1

A Neonatal Case of Infantile Malignant Osteopetrosis Presenting with Thrombocytopenia and Hypotonicity: A Novel Mutation in Chloride Voltage-Gated Channel 7 Gene

Pages
161–165
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of neurological and hematological findings, organomegaly, hearing loss, and vision disorders must attract attention to IMO.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Autosomal recessive osteopetrosis is also known as infantile malignant osteopetrosis (IMO).
📊
Key Findings & Data:The clinical course is often serious and if left untreated, it is fatal in the 1st year of life.
💡
Conclusion & Impact:The presence of neurological and hematological findings, organomegaly, hearing loss, and vision disorders must attract attention to IMO.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Autosomal recessive osteopetrosis is also known as infantile malignant osteopetrosis (IMO). The clinical course is often serious and if left untreated, it is fatal in the 1st year of life. Diagnosis is challenging and often delayed or misdiagnosed. Herein, we present an infant girl who was diagnosed with IMO during evaluations for her hypotonicity and thrombocytopenia. A novel mutation of the chloride voltage-gated channel 7 (CLCN7) gene was also reported. A 10-day-old female patient was referred to our hospital for evaluation of hypotonicity. Her physical examination was normal, other than hypotonicity. Laboratory analysis revealed thrombo- cytopenia and hypocalcemia. In the progress, while she was followed in outpatient clinic, hepatosplenomegaly was detected at the age of 3 months. IMO was suspected with the findings of hepatosplenomegaly, cytopenia, hypocalcemia, difficulty of obtain- ing bone marrow, peripheral smear findings, and hearing loss. The X-ray of the bones was consistent with IMO. A novel pathogenic homozygous c.1504>T (p.Arg502Trp) mutation in CLCN7 gene was revealed. IMO is a rare disorder and it is important to differenti- ate this entity for better clinical outcome. The presence of neurological and hematological findings, organomegaly, hearing loss, and vision disorders must attract attention to IMO.

🔖

Cite This Article

Hazan, F., Al, I. O., Oymak, Y., Gursoy, S., Ozturk, T., Bag, O., Gozmen, S., Karakaya, N., Karapinar, T. H. (2022). A Neonatal Case of Infantile Malignant Osteopetrosis Presenting with Thrombocytopenia and Hypotonicity: A Novel Mutation in Chloride Voltage-Gated Channel 7 Gene. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 56 - Sayı: 1, 161–165. https://ajindex.com/articles/594590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetro- sis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol 2013;9:522–36
  2. Wu CC, Econs MJ, DiMeglio LA, Insogna KL, Levine MA, Orchard PJ, et al. Diagnosis and management of osteopetrosis: consensus guidelines from the Osteopetrosis Working Group. J Clin Endocri- nol Metab 2017;102:3111–23
  3. Penna S, Capo V, Palagano E, Sobacchi C, Villa A. One disease, many genes: implications for the treatment of osteopetroses. Front Endocrinol (Lausanne) 2019;10:85
  4. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathol- ogy. Genet Med 2015;17:405–24
  5. Sobacchi C, Villa A, Schulz A, Kornak U. CLCN7-Related Osteope- trosis. 2007 Feb 12 [updated 2022 Jan 20]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Ame- miya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022
  6. Maximova N, Zennaro F, Gregori M, Boz G, Zanon D, Mbalaviele G. Hematopoietic stem cell transplantation-induced bone remodel- ing in autosomal recessive osteopetrosis: Interaction between skeleton and hematopoietic and sensory nervous systems. Bone 2020;130:115144
  7. Hashemi Taheri AP, Radmard AR, Kooraki S, Behfar M, Pak N, Hamidieh AA, et al. Radiologic resolution of malignant infantile osteopetrosis skeletal changes following hematopoietic stem cell transplantation. Pediatr Blood Cancer 2015;62:1645–9
  8. Zeng B, Li R, Hu Y, Hu B, Zhao Q, Liu H, et al. A novel mutation and a known mutation in the CLCN7 gene associated with relatively stable infantile malignant osteopetrosis in a Chinese patient. Gene 2016;576:176–81
  9. Okamoto N, Kohmoto T, Naruto T, Masuda K, Komori T, Imoto I. Novel CLCN7 compound heterozygous mutations in inter- mediate autosomal recessive osteopetrosis. Hum Genome Var 2017;4:17036
  10. Li L, LV S, Wang C, Yue H, Zhang Z. Novel CLCN7 mutations cause autosomal dominant osteopetrosis type II and intermediate au- tosomal recessive osteopetrosis. Mol Med Rep 2019;19:5030–8
  11. Driessen GJ, Gerritsen EJ, Fischer A, Fasth A, Hop WC, Veys P, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT